Kymera Therapeutics Overview
Kymera Therapeutics Target Price
Analysts' 12-month price predictions for KYMR.
Share Price
$43.64
Average Target Price
$61.00
39.8% upside
39.8% upside3 analysts in the last 4 months
High: $64 | Low: $59
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-06-26 | BTIGJeet Mukherjee | $59 | 35.2% upside |  |
| 2025-06-25 | JefferiesKelly Shi | $64 | 46.7% upside | |
| 2025-06-03 | GuggenheimMichael Schmidt | $60 | 37.5% upside | |
| 2025-02-28 | H.C. Wainwright | $54 | 23.7% upside | |
| 2024-12-05 | BMO CapitalEtzer Darout | $55 | 26% upside | |
| 2024-12-02 | Wells FargoDerek Archila | $57 | 30.6% upside | |
| 2024-09-27 | OppenheimerJeff Jones | $56 | 28.3% upside | |
| 2024-08-26 | Wolfe ResearchAndy Chen | $65 | 48.9% upside | |
| 2024-08-08 | H.C. WainwrightAndrew Fein | $60 | 37.5% upside | |
| 2024-06-17 | H.C. WainwrightAndrew Fein | $46 | 5.4% upside | |
| 2024-05-23 | Piper SandlerEdward Tenthoff | $56 | 28.3% upside | |
| 2024-05-03 | OppenheimerJeff Jones | $52 | 19.2% upside | |
| 2023-01-03 | Wells Fargo | $42 |  3.8% downside | |
| 2022-12-19 | Morgan Stanley | $41 | 6% downside | |
| 2022-12-16 | Goldman Sachs | $52 | 19.2% upside | |
| 2022-12-15 | Leerink Partners | $31 | 29% downside | |
| 2022-12-06 | Morgan StanleyMichael Turits | $45.2 | 3.6% upside | |
| 2022-12-06 | Credit SuisseRichard Law | $32 | 26.7% downside | |
| 2022-08-29 | Morgan Stanley | $37 | 15.2% downside | |
| 2022-08-10 | Credit Suisse | $61 | 39.8% upside | |
| 2022-05-04 | Morgan Stanley | $35 | 19.8% downside | |
| 2022-05-04 | Credit Suisse | $60 | 37.5% upside | |
| 2021-05-20 | UBSEliana Merle | $80 | 83.3% upside | |